We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-30.82%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.7B
AUM Growth
-$1.14B
Cap. Flow
+$29.8M
Cap. Flow %
1.1%
Top 10 Hldgs %
59.73%
Holding
123
New
18
Increased
25
Reduced
16
Closed
19

Top Buys

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$86.4M
2
BABA icon
Alibaba
BABA
+$51.3M
3
NIO icon
NIO
NIO
+$28.5M
4
ALLO icon
Allogene Therapeutics
ALLO
+$10.6M
5
ARRY
Array Biopharma Inc
ARRY
+$9.1M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$31.2M
2
ANAB icon
AnaptysBio
ANAB
+$11.2M
3
FOLD
Amicus Therapeutics
FOLD
+$11M
4
ZGNX
Zogenix, Inc.
ZGNX
+$8.19M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.69M

Sector Composition

Rank Sector Weight
1 Healthcare 48.78%
2 Consumer Discretionary 24.57%
3 Real Estate 0.28%
4 Communication Services 0.12%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRQR icon
26
ProQR Therapeutics
PRQR
$247M
$22.1M 0.82%
1,400,000
+100,000
+8% +$1.84M
ALNY icon
27
CALL
Alnylam Pharmaceuticals
ALNY
$38.2B
$21.9M 0.81%
300,000
+200,000
+200% +$15.4M
FCX icon
28
CALL
Freeport-McMoran
FCX
$85.9B
$20.6M 0.76%
2,000,000
+1,000,000
+100% +$11.7M
AGIO icon
29
Agios Pharmaceuticals
AGIO
$2.09B
$18.4M 0.68%
400,000
+100,000
+33% +$6.17M
IFRX icon
30
InflaRx
IFRX
$247M
$18.2M 0.67%
500,000
– –
XNCR icon
31
Xencor
XNCR
$1.46B
$18.1M 0.67%
500,000
– –
BLUE
32
DELISTED
bluebird bio
BLUE
$17.4M 0.64%
13,510
– –
BMRN icon
33
CALL
BioMarin Pharmaceuticals
BMRN
$11.9B
$17M 0.63%
200,000
– –
AUTL
34
Autolus Therapeutics
AUTL
$381M
$15.6M 0.58%
475,000
-25,000
-5% -$822K
KYNB
35
Kyntra Bio
KYNB
$28.1M
$13.9M 0.51%
12,000
+2,000
+20% +$2.25M
SLDB icon
36
Solid Biosciences
SLDB
$800M
$13.4M 0.5%
33,333
+18,333
+122% +$8.62M
BOLD
37
DELISTED
Audentes Therapeutics, Inc
BOLD
$12.8M 0.47%
600,000
+350,000
+140% +$9.03M
MU icon
38
CALL
Micron Technology
MU
$875B
$12.7M 0.47%
400,000
– –
ALBO
39
DELISTED
Albireo Pharma Inc
ALBO
$12.3M 0.45%
500,000
– –
MDCO
40
CALL
DELISTED
Medicines Co
MDCO
$11.5M 0.43%
600,000
– –
ALLO icon
41
Allogene Therapeutics
ALLO
$618M
$10.8M 0.4%
+400,000
New +$10.6M
DNLI icon
42
Denali Therapeutics
DNLI
$3.78B
$10.3M 0.38%
500,000
– –
CMTA
43
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$10M 0.37%
850,000
+158,000
+23% +$1.97M
BLUE
44
CALL
DELISTED
bluebird bio
BLUE
$9.92M 0.37%
+7,720
New +$11.8M
WYNN icon
45
CALL
Wynn Resorts
WYNN
$10.2B
$9.89M 0.37%
100,000
– –
AAL icon
46
CALL
American Airlines Group
AAL
$9.96B
$9.63M 0.36%
300,000
– –
SAGE
47
DELISTED
Sage Therapeutics
SAGE
$9.58M 0.35%
100,000
– –
ANAB icon
48
AnaptysBio
ANAB
$1.54B
$9.57M 0.35%
150,000
-150,000
-50% -$11.2M
AGIO icon
49
CALL
Agios Pharmaceuticals
AGIO
$2.09B
$9.22M 0.34%
+200,000
New +$12.3M
MLCO icon
50
CALL
Melco Resorts & Entertainment
MLCO
$2.21B
$8.81M 0.33%
+500,000
New +$8.91M
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2018 Portfolio in Review

As of Q4 2018, Artal Group held 123 positions worth $2.7B, down 30% from $3.84B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Artal Group's Q4 2018 filing shows 18 new, 25 increased, 16 reduced and 19 closed positions. Its largest new stake was Moderna: 5,256,298 shares worth $80.3M. The largest sale was TESARO, Inc., an estimated $31.2M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 46% a quarter earlier, followed by Consumer Discretionary and Real Estate.

  • Artal Group's largest Q4 2018 buy was Moderna: 5,256,298 shares worth $80.3M.
  • Artal Group added most to Alibaba in Q4 2018, an estimated $51.3M increase.
  • Artal Group's biggest Q4 2018 reduction was AnaptysBio, cutting an estimated $11.2M.
  • Artal Group fully exited TESARO, Inc. in Q4 2018, selling an estimated $31.2M.
  • Artal Group's ten largest holdings make up 60% of its $2.7B portfolio in Q4 2018.
  • Artal Group opened 18 new positions and closed 19 in Q4 2018.
  • Artal Group's portfolio value fell 30% quarter-over-quarter to $2.7B.

Based on Artal Group's 13F filing for Q4 2018, filed 11 Feb 2019.